Can someone suggest me an antibody suitable for WB analysis to detect human CD38? Thank you!
Here are methods for measuring CD38 described.
http://www.bloodjournal.org/content/111/4/2246.full?sso-checked=true
http://www.bloodjournal.org/content/128/12/1590?rss=1
https://www.researchgate.net/publication/308882048_Osteoclasts_promote_immune_suppressive_microenvironment_in_multiple_myeloma_therapeutic_implication
Regards,
Joachim
Data Osteoclasts promote immune suppressive microenvironment in m...
Hopefully someone else will provide you with a specific recommendation based on personal use, but if not, we can certainly suggest many possible sources for anti-CD38 for WB: https://www.linscottsdirectory.com/antibodies?q=cd38
just select "human" and "WB" from Reactivity and Applications filters. Follow "more info" to suppliers' data pages.
I have never done Western anaylsis on CD38, but I have had excellent results with HIT-2 for flow cytometry, I suspect it would be usable in blots as well.
Hello,
You may check an antibody database at Labome.com. Here is the link to the database page for anti-CD38 antibodies: https://www.labome.com/review/gene/human/CD38-antibody.html. Santa Cruz Biotechnology has several antibodies to human CD38 suitable for Western blot: C-19 (sc-7047) and H-11 (sc-374650) (ref.: Escande et al., J Clin Invest 2010). Also, BD Biosciences provides mouse monoclonal 22/CD38 antibody for Western blot (ref.: Bunaciu et al., PLos One 2015).
Thank you all for your kind reply! I will go through your answers and see which Ab will better satisfy my needs.
Thank you very much!
Targeting CD38 by isatuximab can preferentially block immunosuppressive Tregs and thereby restore immune effector function against multiple myeloma.
Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis) and direct apoptosis with crosslinking. These mechanisms may also target nonplasma cells that express CD38, which prompted evaluation of daratumumab's effects on CD38-positive immune subpopulations.
Another work assessed the antitumor activity of the anti-CD38 antibody SAR650984 and the results validate CD38 as a therapeutic target and support the current evaluation of this unique CD38-targeting functional antibody in phase I clinical trials in patients with CD38+ B-cell malignancies.
https://www.ncbi.nlm.nih.gov/pubmed/24987056
https://www.ncbi.nlm.nih.gov/pubmed/28249894
https://www.ncbi.nlm.nih.gov/pubmed/27222480
Hello Jadson C. Santos ,
Do you have any recommendation of anti-human CD38 mAb that can be used in the culture to block the expression of surface CD38 in human CD4+T cells?
Thank you!
Junfen
Hello Jadson C. Santos ,
Thank you for your responses. But daratumumal is too expensive, as my experiment is at the initial stage. I would like to use less expensive antibody, that can not be therapeutic. Do you have any other recommendations?
Regards,
Junfen
Hello, Junfen,
Daratumumal is the best in this case. Maybe you will need to search and compare the price of other antibodies.
Jadson C. Santos Thank you for your quick response.
Now I am trying to find the blocking antibody, but most of them have not been validated to have the blocking or neutrilization function.
- Badges
- Science topic
- Similar topics
- Biological Science
- Molecular Biology